Genkyotex Provides Business Update and Reports Cash Position at March 31, 2021
Rights issue of €5 million in March 2021 completed
Positive data from Phase 1 clinical trial of high-dose setanaxib
Regulatory News:
Genkyotex (Euronext Paris Brussels: FR0013399474 GKTX) (Paris:GKTX) (Brussels:GKTX), a biopharmaceutical company and the leader in NOX therapies, today reported cash and cash equivalents of €3.8 million as of March 31, 2021. The existing cash and cash equivalents provide cash runway to end of July 2021.
Business update
On March 24, 2021, the Company announced that it had raised €5 million through a rights issue in France. Following this capital increase, the Company s main shareholder, Calliditas Therapeutics AB (publ), holds 90.2% of the share capital and voting rights of the Company.
1
1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, United States
3Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, United States
4Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, United States
Tumor-stromal interactions within the tumor microenvironment (TME) influence lung cancer progression and response to therapeutic interventions, yet traditional
in vitro studies fail to replicate the complexity of these interactions. Herein, we developed three-dimensional (3D) lung tumor models that mimic the human TME and demonstrate tumor-stromal crosstalk mediated by extracellular vesicles (EVs). EVs released by tumor cells, independent of p53 status, and fibroblasts within the TME mediate
Genkyotex: Disclosure of the Total Number of Voting Rights and Shares Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority
Regulatory News:
Genkyotex shares
Date
(1): 14,083,408
meeting
(2): 14,074,165
(1) In accordance with Article 223-111 of the AMF s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
(2) Less shares stripped of voting rights.
About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. Its unique platform enables the identification of orally available small-molecules which selectively inhibit specific NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. Genkyotex is developing a pipeline
Genkyotex: Disclosure of the total number of voting rights and shares pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority
Regulatory News:
Genkyotex shares
Date
(1): 11,736,174
(2): 11,726,931
(1)
In accordance with Article 223-111 of the AMF s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
(2)
About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. Its unique platform enables the identification of orally available small-molecules which selectively inhibit specific NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. Genkyotex is developing a pipeline of first-in-class product candidates targeting